PCM
CSTL icon

Palisade Capital Management’s Castle Biosciences CSTL Stock Holding History

Palisade Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.53M Sell
231,931
-303,953
-57% -$6.77M 0.24% 129
2026
Q1 		$13.2M Sell
535,884
-31,893
-6% -$1.04M 0.44% 87
2025
Q4 		$22.1M Sell
567,777
-70,879
-11% -$2.29M 0.65% 59
2025
Q3 		$14.5M Buy
638,656
+63,540
+11% +$1.29M 0.4% 90
2025
Q2 		$11.7M Buy
575,116
+85,148
+17% +$1.58M 0.33% 97
2025
Q1 		$9.81M Sell
489,968
-13,474
-3% -$334K 0.28% 111
2024
Q4 		$13.4M Buy
503,442
+1,125
+0.2% +$34.3K 0.36% 96
2024
Q3 		$14.3M Sell
502,317
-35,657
-7% -$908K 0.38% 90
2024
Q2 		$11.7M Sell
537,974
-9,193
-2% -$205K 0.32% 101
2024
Q1 		$12.1M Buy
547,167
+8,032
+1% +$175K 0.32% 102
2023
Q4 		$11.6M Sell
539,135
-63,126
-10% -$1.11M 0.31% 103
2023
Q3 		$10.2M Buy
602,261
+57
+0% +$997 0.28% 107
2023
Q2 		$8.26M Buy
602,204
+25,186
+4% +$510K 0.22% 129
2023
Q1 		$13.1M Buy
577,018
+25,923
+5% +$633K 0.35% 96
2022
Q4 		$13M Sell
551,095
-28,849
-5% -$669K 0.35% 96
2022
Q3 		$15.1M Buy
579,944
+1,011
+0.2% +$28.3K 0.43% 78
2022
Q2 		$12.7M Buy
578,933
+169,701
+41% +$3.94M 0.34% 91
2022
Q1 		$18.4M Buy
409,232
+56,791
+16% +$2.35M 0.42% 80
2021
Q4 		$15.1M Buy
+352,441
New +$18.4M 0.31% 104

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Palisade Capital Management's CSTL Position: Q2 2026 in Review

Palisade Capital Management reduced its Castle Biosciences (CSTL) stake by 57% in Q2 2026, selling an estimated $6.77M and leaving 231,931 shares worth $5.53M. The position accounts for 0.24% of the portfolio, ranked #129.

Palisade Capital Management first reported a position in CSTL in Q4 2021 and has held it in 19 quarters since. The position peaked at $22.1M in Q4 2025. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Palisade Capital Management held 231,931 shares of Castle Biosciences worth $5.53M as of Q2 2026.
  • Palisade Capital Management sold 303,953 Castle Biosciences shares in Q2 2026, an estimated $6.77M.
  • Castle Biosciences made up 0.24% of Palisade Capital Management's portfolio in Q2 2026, its #129 holding.
  • Palisade Capital Management first reported a position in Castle Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Palisade Capital Management's Castle Biosciences position peaked at $22.1M in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Palisade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.